Key facts
- Biohaven initiated a first-in-human study for BHV-8100.
- BHV-8100 is an orally administered, brain-penetrant PKM2 modulator.
- The drug targets the bioenergetic and immunometabolic basis of systemic and CNS disorders.
- Dose escalation is ongoing in the study.
BHV-8100 represents a novel therapeutic approach by targeting PKM2, a key enzyme in cellular metabolism. By modulating PKM2, Biohaven aims to address underlying bioenergetic and immunometabolic dysfunctions implicated in a range of systemic and neurological conditions. The initiation of a first-in-human study marks a significant step in evaluating the safety and potential efficacy of this new class of drugs.